# CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

> **NCT04222842** · PHASE1 · SUSPENDED · sponsor: **AnewPharma** · enrollment: 96 (estimated)

## Conditions studied

- Myopic Choroidal Neovascularisation

## Interventions

- **DRUG:** CM082

## Key facts

- **NCT ID:** NCT04222842
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-12-18
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 96 (ESTIMATED)
- **Why stopped:** Day is not required for Anticipated dates.
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222842, "CM082 in Patients With Myopic Choroidal Neovascularization (CNV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04222842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*